Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
T-lymphoblastic leukemia/lymphoma resistant to treatment
Biomarker and diagnostic research for refractory precursor T-lymphoblastic lymphoma/leukemia has been reported in the published literature.
1 clinical trial registered, 1 recruiting. Interventions under study include biologic therapy. Pipeline includes 1 PHASE2. Research is primarily industry-sponsored.
151 publications have been identified in PubMed for refractory precursor T-lymphoblastic lymphoma/leukemia. Research spans Clinical Trial Publication (34%), Review / Meta-Analysis (28%), and Basic Science / Preclinical (16%).
Research Type | Count | % of Total |
|---|---|---|
Clinical study results | 51 |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 8:41 AM UTC
Research summaries | 43 | 28% |
Laboratory research | 24 | 16% |
New treatment approaches | 17 | 11% |
Patient case studies | 6 | 4% |
Disease patterns and progression | 6 | 4% |
Testing and diagnosis research | 3 | 2% |
Other research | 1 | 1% |
Cosgun KN (2026). [PMID: 41507538](https://pubmed.ncbi.nlm.nih.gov/41507538/). *Nat Cancer*. [Basic Science / Preclinical]
Goldberg L (2026). [PMID: 41720802](https://pubmed.ncbi.nlm.nih.gov/41720802/). *Nat Commun*. [Basic Science / Preclinical]
Lee J (2026). [PMID: 41666265](https://pubmed.ncbi.nlm.nih.gov/41666265/). *Sci Signal*. [Basic Science / Preclinical]
Yu J (2026). [PMID: 41776492](https://pubmed.ncbi.nlm.nih.gov/41776492/). *BMC Med*. [Clinical Trial Publication]
Pölönen P (2026). [PMID: 41954523](https://pubmed.ncbi.nlm.nih.gov/41954523/). *Blood Cancer Discov*. [Review / Meta-Analysis]
Lecornec N (2026). [PMID: 41735483](https://pubmed.ncbi.nlm.nih.gov/41735483/). *Leukemia*. [Epidemiology / Natural History]
Gava F (2026). [PMID: 41707115](https://pubmed.ncbi.nlm.nih.gov/41707115/). *Blood Adv*. [Review / Meta-Analysis]
Zahra T (2026). [PMID: 41632382](https://pubmed.ncbi.nlm.nih.gov/41632382/). *Curr Hematol Malig Rep*. [Review / Meta-Analysis]
Yao X (2026). [PMID: 40974407](https://pubmed.ncbi.nlm.nih.gov/40974407/). *Eur J Nucl Med Mol Imaging*. [Diagnostic / Biomarker]
Zhang L (2026). [PMID: 40628245](https://pubmed.ncbi.nlm.nih.gov/40628245/). *Acta Haematol*. [Clinical Trial Publication]